Cytomx Therapeutics Inc., of South San Francisco, said Bristol-Myers Squibb Co., of New York, has selected a clinical candidate for its CTLA-4 Probody program under the companies' strategic oncology collaboration established in May 2014, resulting in a $2 million milestone payment to Cytomx.